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Abstract
IgA nephropathy (IgAN) is the most common primary Background: glomerulonephritis and an important cause of end-stage kidney disease. Unlike the slowly progressive course seen among Caucasian and East Asian subjects (actuarial survival 80-85% over 10 years), in India about 30-40% of patients have nephrotic syndrome and renal dysfunction at presentation and a 10-year renal survival of 35%, as reported from a retrospective registry. These observations cannot be entirely attributed to a lack of uniform screening protocols or late referral and attest to the probability that IgAN may not be the same disease in different parts of the world.
We will prospectively recruit 200 patients with IgAN (the GRACE Methods: IgANI-lomerular esearch nd linical xperiments-g ephropathy in G R A C E I A N I ndians-cohort) and stratify them into low and high risk of progression based on published absolute renal risk scores. We will test the validity of this risk score in an unselected Indian IgAN population over a 5-year follow-up period.
In parallel, we will undertake extensive exploratory serum, urine, renal and Referee Status: What is known in South Asia and India Incidence of glomerular disease in the tropics is much greater than in temperate countries. Nephrotic syndrome is 60-100 times more common in India than in the UK and USA 3 . Glomerular diseases are often a consequence of interaction between an environmental nephritogenic antigen and a genetically susceptible host. Hence, the high rate of antigenic exposure in the tropics could account for this high incidence of glomerulonephritis. There is no national glomerulonephritis registry in India. Most epidemiological studies are single-or multi-centre retrospective analyses of renal biopsy datasets.
The most common presentation of primary glomerulonephritis in various studies in India is nephrotic syndrome and renal impairment (Table 1) . Asymptomatic urinary abnormalities are reported far less frequently (1.7-9%) 4 ,5 when compared to data from registries in other developed nations like Japan and Italy 6,7 . This is perhaps not surprising as there is no universal urine screening program in India, precluding detection of the disease at an early asymptomatic stage. IgAN is the most common primary glomerulonephritis in India, identified in 10-15% of all renal biopsies reported from our institution and elsewhere in India 4, 5, 8, 9 . Retrospective studies from renal registries in India report that 30-40% of patients with IgAN have nephrotic syndrome and renal dysfunction at presentation 4,9-11 . Indian patients present with IgAN approximately over a decade earlier than Caucasian and East Asian patients, whose average age at presentation is 35-40 years [12] [13] [14] . These observations cannot be entirely attributed to differences in access to primary care and countryspecific screening programs for kidney disease, and attest to the likelihood that IgAN may not be the same disease in different parts of the world.
George et al. 15 , at Christian Medical College, Vellore, India (CMC Vellore), reported IgAN in 9.6% of 649 adults with Chacko et al. (CMC Vellore) reported that four factors were significantly associated with ESKD. These were hypertension, nephrotic range proteinuria, degree of sclerosed glomeruli, and interstitial fibrosis at presentation. The mean renal survival time of patients without any of these was 132 months, whereas those with one, two, or three risk factors were 105, 47, and 28 months, respectively (Figure 1) . A total of 46% of patients either progressed to ESKD or had permanent decline in renal function at last follow-up. Overall renal survival at 10 years was only 35% when compared with nearly 90% in similar studies from Singapore, Australia, and France. Also, patients diagnosed from the year 2000 onward had poorer outcomes, than those diagnosed before the year 2000 22, 23 . . This reduction in the number of O-linked galactose residues at the IgA1 hinge has been detected using specific lectin binding assays, fluorophore-assisted carbohydrate electrophoresis and mass spectrometry 36 . These IgA1 molecules have been shown to activate human mesangial cells in vitro 37 resulting in the generation of IgG and IgA1 anti-hinge region autoantibodies and circulating immune complexes that leads to activation of the complement system through the lectin and alternative pathways 38, 39 . Patients with IgAN have higher levels of poorly galactosylated IgA1 in their serum than healthy subjects 40, 41 , and these levels appear to correlate with a higher In this study, we will assess the correlation between clinical and histological features, and measures of immunological activation in a cohort of Indian patients with IgAN. We will use our understanding of the pathogenesis of IgAN in Caucasians and East Asians to determine whether factors such as serum levels of secretory IgA, IgA immune complexes and IgG anti-hinge region autoantibodies can be used to risk stratify patients and monitor response to immunotherapy in an Indian population.
The Kidney Disease Improving Global Outcomes (KDIGO) guidelines on glomerulonephritis 48 do not recommend immunosuppression in most patients with IgAN. However, considering the severe presentation and progression of IgAN in India, the standard protocol for managing patients with IgAN at CMC Vellore is to treat with immunosuppression in those who have a urinary protein excretion >1 g/day with/without renal dysfunction along maximally tolerated inhibition of the renin-angiotensin system (RAS). We give oral prednisolone at 2 mg/kg alternate days (max. 120 mg) for 3 months and then taper and stop over the next 3 months. Mycophenolic acid is added as a second immunosuppressor at 25-30 mg/kg, with monitoring of area under the curve (target 30-50 mg.h/l), if they are persistently nephrotic with or without renal dysfunction and if the therapy is affordable to the patient. The treatment dilemma in IgAN has been highlighted recently 49 and we will carefully monitor the effects of immunosuppression in this cohort.
Protocol
We hypothesise that the natural history and risk of renal progression in Indian patients with IgAN differs from that widely reported for Caucasian and East Asian patients. This may be due to differences in the underlying pathogenic pathways operating in Indian patients. A completed STROBE reporting checklist is available (Supplementary File 1) .
Primary objective
• To measure exploratory biomarkers in an incident Indian population with IgAN and look for associations with clinical outcomes at 2 and 5 years of follow-up.
Secondary objectives
• To measure exploratory biomarkers in an incident Indian population of IgAN and compare these findings with biomarker studies in Caucasian and East Asian IgAN populations to determine whether pathogenic pathways are similar across ethnicities.
• To determine the impact of immunosuppressive agents on the levels of selected biomarkers in an Indian IgAN population.
• To develop renal risk score for Indian patients with IgAN to help counsel patients at the time of diagnosis and direct health resources and immunosuppressive therapy to those patients at greatest risk of ESKD.
Patient recruitment
The study will be conducted in the Department of Nephrology, CMC Vellore. CMC Vellore is the largest private not-for-profit tertiary referral hospital in South India and caters to patients mainly from South, North and North-East India. All patients being planned for a renal biopsy at CMC Vellore will be screened and all eligible patients will be approached to participate in the study. The inclusion and exclusion criteria are given in Table 2 . These criteria apply to all IgAN and non-IgAN participants. Table 2 . Inclusion and exclusion criteria for screening patient eligibility prior to recruitment into the GRACE-IgANI cohort study.
Inclusion criteria Exclusion criteria
Age ≥18 years Secondary IgA nephropathy: e.g. due to lupus, liver cirrhosis, Henoch-Schonlein purpura.
Primary IgAN diagnosed by renal biopsy Glomerular filtration rate as estimated by the CKD-EPI equation <10 ml/min/1.73 m 2 .
Immunosuppression naive for three months prior to recruitment
Patients with systemic diseases that can affect the kidneys like diabetes, systemic lupus erythematosus, presence of HIV, HBsAg, HCV infections, malignancies etc.
Willing to come for follow-up visits Patients with a history of psychological illness or condition which interferes with their ability to understand or comply with the requirements of the study.
IgAN, IgA nephropathy; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus.
All consenting patients will be recruited prior to the renal biopsy procedure. IgA nephropathy will be diagnosed by the presence of IgA-dominant or co-dominant immune deposits within glomeruli, as shown by immunofluorescent staining of the renal biopsy tissue
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. The non-IgAN kidney disease control arm will be patients with biopsy-proven primary glomerulonephritis other than IgAN. The healthy control group will be matched for age and gender to the IgAN cohort and will be voluntary kidney donors on work-up for kidney donation. Both arms will be matched in terms of sample size. The Caucasian and East Asian patient cohorts will be obtained from the University of Leicester, IgA nephropathy lab database, and the main collaborator for this work is J.B. Details concerning enrollment and ethical approval of this arm have been previously published 50 . Some of the initial biomarkers we propose to test in sera are levels of galactose-deficient IgA1, immune complexes, antibody to galactose-deficient IgA1, secretory IgA, immune cell markers among other exploratory biomarkers to be determined during the study. The renal tissue will also be stained for components of the alternative and lectin pathways and for IgA1 components. The study started patient recruitment in March 2015 and ended at the last quarter of 2017. All patients are being followed up prospectively.
Outcome measures Primary outcome
The primary outcome is the evaluation of a range of aforementioned exploratory serum, urine and renal biomarkers and the investigation of their association to the rate of fall in estimated glomerular filtration rate (eGFR) at 2 and 5 years in a low-and high-risk incident Indian IgAN population as defined by ARR scores of <23 and of ≥23 points, respectively, at baseline and for the whole cohort.
Secondary outcomes
1. Evaluation of a range of exploratory serum, urine and renal biomarkers, and to investigate their association to a composite end-point of at-least 50% decline in eGFR and ESKD (eGFR <15 ml/min/1.73 m 2 ), renal replacement therapy (RRT) or death at 2 and 5 years in a low-and high-risk incident Indian IgAN population as defined by an ARR score of <23 and of ≥23 points, respectively, at baseline and for the whole cohort.
2. To determine the validity of the ARR to predict either the rate of fall in eGFR or a composite end-point of at least 50% decline in eGFR and ESKD (eGFR <15 ml/min/1.73 m 2 ), RRT or death at 2 and 5 years in an unselected incident Indian population with IgAN. 4. To determine whether the addition of novel biomarker measurements can improve the predictive performance of an RRS in an Indian IgAN population.
5. To determine whether selected biomarker levels measured at baseline and serially during follow-up are influenced by the use of immunosuppression.
To develop an RRS for Indian patients with IgAN.

Sample size
Patients will be classified as being at low risk of progressive renal disease if their ARR score is <23 points or high risk if their ARR score of ≥23 points at baseline 31 . Based on previous studies in India, we have assumed that the frequency of rapid progressors (>5 ml/min/1.73 m 2 /year fall in eGFR) in the lowrisk group will be 5%, and in the high-risk group will be 20% 17, 23 . So, 176 patients give a power of 80% with an alpha error of 5% for detecting significant difference between proportions. Considering a 15% dropout rate (non-compliance to follow-up visits, unplanned pregnancies), 200 patients were recruited prospectively over 2.5 years (from March 2015 until the last quarter of 2017). We will look for significant differences among the exploratory biomarkers between the two risk groups and as independent variables to predict progressive decline in renal function and a composite end-point of at least 50% decline in eGFR and ESKD (eGFR <15 ml/min/1.73 m 2 ), renal replacement therapy (RRT) or death. We would like to find the best cut-off of the ARR score using received operating characteristic (ROC) curve methods. The best threshold will be obtained using likelihood ratio statistics, that is, by aiming to have high specificity with a high positive predictive value. However, the utility of the ROC will be decided based on the AUC. As part of the study apart from evaluating whether a different ARR threshold improves precision, we will also study whether addition of new biomarkers to an optimised Indian RRS improves the predictive value in an Indian population-this will include the C score of the new MEST-C score and exploratory biomarkers measured at baseline. At the same time, we will evaluate the accuracy in the Caucasian cohort and determine the additive value of additional measures to help predict Caucasian and Indian risk separately. In order to validate the usefulness of the threshold, another prospective validation cohort with a known threshold will be set up and followed to study the prognosis. However, in order to establish reliable CIs for the validity statistics bootstrap method (with 10,000 resampling) will be done in this cohort. We will include an equivalent number of healthy and disease controls to match the sample size of IgA patients. They will not be followed up longitudinally and will only be included in cross-sectional analyses at baseline.
Study procedures and timeline
This is a prospective longitudinal cohort study with consecutive recruitment of incident IgAN patients. The baseline assessments will include the collection of demographic details, a physical examination, standard clinical laboratory tests and collection of biological samples (DNA, serum, plasma, renal tissue, urine and faeces) for future biomarker and microbiomic analysis 46 . Patients will be followed at least annually (usually 2-3 visits per year) and at each visit standard laboratory testing, alongside the collection of biological samples for exploratory analysis, will be undertaken. The study co-ordinators will also contact patients telephonically or through postal/email correspondence to assess their adherence to medications, optimise the doses of RAS blockers according to the self-reported blood pressure and renal function tests. There will be a pre-specified interim analysis of the cohort once all patients have completed 2 years of follow-up. All patients will be followed-up for 5 years. Timelines for recruitment and follow-up visits are summarized in Figure 2 .
Statistical analysis
Demographic data on patients will be gathered and suitable comparisons will be made to ensure that the groups are wellmatched. All outcome measures will undergo appropriate omnibus tests to investigate statistical differences between groups and within groups. Risk factors for progressive disease in an Indian population will be evaluated using a Cox proportional hazard model with a stepwise backward elimination method and then compared with those comprising the ARR score derived from a Japanese cohort. To create a renal prediction risk score specifically for Indian IgAN (either a modified ARR or completely new score), incorporating measures of exploratory biomarkers, the score for each variable will be weighted by the regression coefficients calculated using the relevant Cox model. In addition to this, we will look at associations between outcome measures and investigate potential interactions between variables to generate hypotheses for future studies. All statistical analyses will be done using SPSS version 21 and GraphPad (Prism) version 7.
Patient and public involvement
This observational study has been designed based on the retrospective data from our institute 22,23 and the felt need of all stakeholders for urgent research in this area. The patients and the public were not involved in the design or conduct of this study, but they are the intended benefactors of this research. The results will be disseminated electronically to all participants in the study.
Strengths and limitations
Strengths of this protocol include the fact that this is a prospective longitudinal design with consecutive recruitment, reducing recruitment bias and enabling longitudinal biomarker evaluations. To our knowledge, this is also the first South Asian IgAN cohort to be established. In addition, bio-banking of clinical samples to a standardised protocol for future research will enable us to test emerging hypotheses on a well-established cohort.
Limitations of this protocol include the fact that pediatric (those aged <18 years) cases are excluded and limits the results interpretation to only adult patients. Additionally, participants with advanced kidney disease (eGFR <10 ml/min/1.73 m 2 ) are excluded so study conclusions may not reflect this subset of individuals.
Ethics and dissemination
The full protocol was presented to the Institutional Review Board 
Dissemination plan
We plan to present all data at national and international conferences. Furthermore, we will also publish the findings in international journals. We expect to publish our initial findings during late 2018. Following the publication of our results, anonymised participant level data will be available for collaborations, on request. The GRACE-IgANI study is registered with the ISRCTN (ISRCTN36834159) and the registration status is retrospective as patient recruitment started before registration.
Data availability
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This adds to the work already being done by members of the group who have international expertise in studies of the pathogenesis and epidemiology of IgAN.
The background and methods are clearly stated. I answered 'partly' to the question about the methods being presented sufficiently to be replicated simply because not all of the biomarkers to be assessed have been identified yet.
There are many strengths to the proposed study. In particular the fact that one of the cohorts for study has already been recruited. I was slightly confused about whether the subjects for the Indian cohort had already been recruited; the 'Patient recruitment' section implied they have not and the 'Sample Size' section implied they have.
One potential limitation is the effect that immunosuppression might have on the longitudinal outcomes both in terms of renal function and biomarkers. The authors highlight that use of immunosuppression for IgAN is common in India and more common than will be the case in the caucasian cohort. They will recruit immunosuppression naïve subjects at baseline but it is not clear how they will handle the potential impact of subsequent immunosuppression.
Overall I think this study has the potential to add greatly to current knowledge and to the work already being done by this research collaboration.
Is the rationale for, and objectives of, the study clearly described? The protocol is well written and I cannot wait to read the results of this study which will provide essential information in the field of IgA nephropathy.
Nevertheless, the paper could be improved by detailing some points:
If I understand correctly, 4 groups of patients will be compared: Indian patients with NIgA, Caucasian and East Asian patients with NIgA, Indian patients with primary nephropathy other than NIgA and healthy patients (kidney donors). As the first group of patients is well described, the other 3 lack details and in particular we should modify Figure 2 by distinguishing the 4 groups and their respective numbers.
In addition, some patients will be treated, which ones? With which treatment? Again, there is a lack of detail since we imagine that it is mainly the high-risk patients who will be treated with a certain risk of bias and if many groups of treatments are applied, the risk of loss of power in the analysis will be important.
The primary endpoint is unclear: what rate of decline in GFR? Define patients with good or bad evolution... Finally, a table summarizing the prognostic factors (biomarkers) which will be evaluated could be added.
Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
